Celltrion Healthcare Co., Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Celltrion Healthcare Co., Ltd.
Celltrion Healthcare was ultimately able to increase its revenue by 16.7%, with stronger growth expected in H2.
The European Commission is expected to make a “rapid decision” on the European Medicines Agency’s recommendation today that Evusheld should be approved.
Celltrion’s Remsima infliximab biosimilar has won a Brazilian federal tender as well as several individual state bids, following earlier awards for the Korean firm’s Truxima (rituximab) and Herzuma (trastuzumab) biosimilars.
Orphan drugs and COVID-19 products are among the latest filings under review by the European Medicines Agency for potential pan-EU approval.